Tisolagiline

From WikiMD.com Medical Encyclopedia

Overview of the drug Tisolagiline


Tisolagiline
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG


Tisolagiline, also known by its developmental code name TV-3326, is a selective monoamine oxidase B inhibitor (MAO-B inhibitor) that has been investigated for its potential use in the treatment of neurodegenerative disorders, such as Parkinson's disease and Alzheimer's disease.

Pharmacology[edit | edit source]

Tisolagiline functions primarily as a selective inhibitor of the enzyme monoamine oxidase B (MAO-B). This enzyme is responsible for the breakdown of dopamine in the brain, and its inhibition leads to increased levels of dopamine. This mechanism is particularly beneficial in the treatment of Parkinson's disease, where dopamine levels are pathologically low.

Unlike non-selective monoamine oxidase inhibitors (MAOIs), selective MAO-B inhibitors like Tisolagiline do not require dietary restrictions to avoid tyramine-induced hypertensive crisis, making them safer and more convenient for patients.

Potential Therapeutic Uses[edit | edit source]

Tisolagiline has been studied for its potential benefits in several neurodegenerative conditions:

Parkinson's Disease[edit | edit source]

In Parkinson's disease, the progressive loss of dopaminergic neurons leads to motor symptoms such as tremor, rigidity, and bradykinesia. By inhibiting MAO-B, Tisolagiline may help to alleviate these symptoms by increasing the availability of dopamine in the brain.

Alzheimer's Disease[edit | edit source]

Research has also explored the use of Tisolagiline in Alzheimer's disease, where it may exert neuroprotective effects. The exact mechanism by which MAO-B inhibitors could benefit Alzheimer's patients is not fully understood, but it is hypothesized that they may reduce oxidative stress and neuronal damage.

Development and Research[edit | edit source]

Tisolagiline was developed by Teva Pharmaceutical Industries and has undergone various stages of clinical trials. However, as of the latest updates, it has not been approved for clinical use. The research into Tisolagiline highlights the ongoing efforts to find effective treatments for neurodegenerative diseases, which remain a significant challenge in modern medicine.

Chemical Properties[edit | edit source]

Tisolagiline is a small molecule with the chemical formula C13H17NO. Its structure includes an indanamine moiety, which is crucial for its activity as an MAO-B inhibitor.

Chemical structure of Tisolagiline

Related pages[edit | edit source]

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD